Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Gains from Investment Securities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Gains from Investment Securities for 11 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 68.61% to -$1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 188.68% increase, with the full-year FY2024 number at $415000.0, changed N/A from a year prior.
  • Gains from Investment Securities was -$1.2 million for Q3 2025 at Editas Medicine, up from -$1.8 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $19.8 million in Q4 2022 to a low of -$9.8 million in Q4 2021.
  • A 5-year average of $1.3 million and a median of $460000.0 in 2022 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 2234.41% in 2021; the steepest drop was 2347.24% in 2021.
  • Editas Medicine's Gains from Investment Securities stood at -$9.8 million in 2021, then soared by 303.39% to $19.8 million in 2022, then plummeted by 92.02% to $1.6 million in 2023, then surged by 135.06% to $3.7 million in 2024, then crashed by 131.39% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Gains from Investment Securities are -$1.2 million (Q3 2025), -$1.8 million (Q2 2025), and $766000.0 (Q1 2025).